ReviewMedical oncology (Northwood, London, England)2026
Thioredoxin-Binding protein 2 and apoptosis Signal-Regulating kinase 1: redox stress sensors and therapeutic targets in hepatocellular carcinoma.
Review in Medical oncology (Northwood, London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) develops under sustained oxidative and inflammatory stress, where thioredoxin-binding protein 2 (TBP2/TXNIP) and apoptosis signal-regulating kinase 1 (ASK1/MAP3K5) act as central redox sensors. Under basal conditions, TBP2 inhibits reduced thioredoxin, enabling ASK1 activation and c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase (p38 MAPK) signaling to promote apoptosis, senescence, and immune surveillance. In HCC, transcriptional repression, epigenetic silencing, and post-transcriptional regulation downregulate TBP2 and ASK1, fostering tumor cell survival, metabolic adaptation, and immune evasion. Both proteins intersect with the NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome, which induce pyroptosis and provides antitumor immunity. This review synthesizes current mechanistic insights into TBP2/ASK1 regulation, their integration with redox and inflammasome signaling, and modulation by natural compounds such as curcumin, piperine and other natural compounds. We also examine therapeutic approaches including gene therapy, epigenetic reactivation, and redox-modulating agents. Translational challenges include context-dependent effects, biomarker limitations, and delivery specificity. Refining strategies to achieve precise, transient TBP2/ASK1 activation may unlock their tumor-suppressive potential while minimizing inflammatory risk, offering a novel avenue for HCC treatment.
Indexed as
Identifiers
41563678What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.